AGENCY OVERVIEW
ARPA-H was established in 2022 with an initial $1 billion budget (expanded to $2.5B by 2024) to drive breakthrough health research. Modeled after DARPA's high-risk, high-reward approach, the agency funds transformative projects in cancer, Alzheimer's, diabetes, and emerging infectious diseases that traditional funding mechanisms cannot support.
PROTEUS PROGRAM
- Focus: Programmable therapeutics and next-generation biologics
- Goal: Create adaptable biological systems for personalized medicine
- Applications: CAR-T optimization, gene editing delivery, synthetic biology
- Investment: $100M+ across multiple performer teams
KEY HEALTH OFFICE INITIATIVES
- HEAL: Health science futures for pandemic preparedness
- RESILIENT: Proactive health through wearables and early detection
- POSEIDON: Precision surgery and minimally invasive interventions
- PARADIGM: Platform acceleration for rapid countermeasure development
RELEVANCE TO PATIENT ANALOG
ARPA-H programs directly advance human simulation technologies through funding for organ-on-chip platforms, AI-driven drug discovery, and precision medicine infrastructure. The agency's emphasis on reducing time-to-clinic aligns with NAMs adoption goals.